deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03371381

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

An Open-Label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced Adenocarcinoma of the Lung

Sponsor: Janssen Research & Development, LLC

Conditions Adenocarcinoma of Lung
Interventions JNJ-64041757 Nivolumab
Updated 17 times since 2017 Last updated: Jan 31, 2025 Started: Jan 2, 2018 Primary completion: Oct 9, 2018 Completion: Oct 9, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical benefit observed in the Phase 1b portion of the study

Other terminated trials from Janssen Research & Development, LLC

More terminations from Janssen Research & Development, LLC

Other Adenocarcinoma of Lung trials with similar outcome

Browse all Adenocarcinoma of Lung trials

Listed as NCT03371381, this PHASE1/PHASE2 trial focuses on Adenocarcinoma of Lung and remains terminated or withdrawn. Sponsored by Janssen Research & Development, LLC, it has been updated 17 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2020 · 13 months · monthly snapshot~Jan 2020 – ~Nov 2020 · 10 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Mar 2025 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Sep 2024 — Mar 2025 [monthly]

    Terminated PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  3. Jan 2020 — Nov 2020 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2018 — Jan 2020 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  5. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Dec 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Research & Development, LLC
Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations